There are currently 441 clinical trials in Las Vegas, Nevada looking for participants to engage in research studies. Trials are conducted at various facilities, including Comprehensive Cancer Centers of Nevada, University Medical Center of Southern Nevada, Summerlin Hospital Medical Center and GSK Investigational Site. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease
NCT05174169
Recruiting
This Phase II/III trial will evaluate the what kind of chemotherapy to recommend to patients based on the presence or absences of circulating tumor DNA (ctDNA) after surgery for colon cancer.
Gender:
All
Ages:
18 years and above
Trial Updated:
06/05/2024
Locations: OptumCare Cancer Care at Charleston, Las Vegas, Nevada +3 locations
Conditions: Stage III Colon Cancer
Register for Updates
A Dose-ranging Study in Patients With Diabetic Peripheral Neuropathic Pain (DPNP)
NCT06203002
Recruiting
Evaluation of the efficacy of LX9211 compared to placebo in reducing DPNP.
Gender:
All
Ages:
18 years and above
Trial Updated:
06/05/2024
Locations: Lexicon Investigational Site (162), Las Vegas, Nevada
Conditions: Diabetic Peripheral Neuropathic Pain
Register for Updates
A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma
NCT05100862
Recruiting
The purpose of the study is to compare the efficacy of zanubrutinib plus obinutuzumab versus lenalidomide plus rituximab (R^2) in participants with relapsed/refractory (R/R) follicular lymphoma (FL), as measured by progression-free survival as determined by an independent review committee in accordance with the 2014 modification of the International Working Group on non-Hodgkin lymphoma (NHL) Criteria based on n positron emission tomography and computed tomography (PET/CT), and to compare the ef... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
06/05/2024
Locations: Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada
Conditions: Relapsed/Refractory Follicular Lymphoma, Marginal Zone Lymphoma
Register for Updates
Tumor-Agnostic Precision Immuno-Oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study
NCT04589845
Recruiting
TAPISTRY is a Phase II, global, multicenter, open-label, multi-cohort study designed to evaluate the safety and efficacy of targeted therapies or immunotherapy as single agents or in rational, specified combinations in participants with unresectable, locally advanced or metastatic solid tumors determined to harbor specific oncogenic genomic alterations or who are tumor mutational burden (TMB)-high as identified by a validated next-generation sequencing (NGS) assay. Participants with solid tumors... Read More
Gender:
All
Ages:
All
Trial Updated:
06/05/2024
Locations: Comprehensive Cancer Centers of Nevada - Eastern Avenue, Las Vegas, Nevada
Conditions: Solid Tumors
Register for Updates
A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies
NCT05006716
Recruiting
Study consists of two main parts to explore BGB-16673 recommended dosing, a Phase 1 monotherapy dose finding comprised of monotherapy dose escalation and monotherapy safety expansion of selected doses, and a Phase 2 (expansion cohorts)
Gender:
All
Ages:
18 years and above
Trial Updated:
06/05/2024
Locations: Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada
Conditions: B-cell Malignancy, Marginal Zone Lymphoma, Follicular Lymphoma, Non-hodgkin Lymphoma, Waldenström Macroglobulinemia, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Mantle Cell Lymphoma, Diffuse Large B Cell Lymphoma
Register for Updates
Phase 2a Study to Assess the Efficacy and Safety of AZD4604 in Adult Patients With Moderate-to-Severe Asthma Uncontrolled on Medium-High Dose ICS-LABA
NCT06020014
Recruiting
This is a Phase 2a, multicentre, randomised, placebo-controlled, double-blind, parallel-group study to evaluate the efficacy, safety and PK of AZD4604 administered BID using a dry-powder inhaler at one dose level over a 12-week Treatment period in adult participants with uncontrolled moderate-to-severe asthma.
Gender:
All
Ages:
Between 18 years and 80 years
Trial Updated:
06/05/2024
Locations: Research Site, Las Vegas, Nevada
Conditions: Asthma
Register for Updates
A Study With Self-administered Rocatinlimab in Adolescent and Adult Participants With Moderate-to-severe AD
NCT06224192
Recruiting
The primary objective of this study is to assess successful self-administration of rocatinlimab subcutaneous using devices for injection at home.
Gender:
All
Ages:
Between 12 years and 100 years
Trial Updated:
06/05/2024
Locations: Excel Clinical Research, Las Vegas, Nevada
Conditions: Atopic Dermatitis
Register for Updates
Long-term Extension Study of Zanubrutinib (BGB-3111) Regimens in Participants With B-cell Malignancies
NCT04170283
Recruiting
The purpose of this study is to evaluate the long-term safety of zanubrutinib regimens in participants with B-cell malignancies who participated in a BeiGene parent study for zanubrutinib.
Gender:
All
Ages:
18 years and above
Trial Updated:
06/05/2024
Locations: Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada
Conditions: B-cell Malignancies
Register for Updates
Development and Validation of Harbinger Health Test for Early Cancer Detection
NCT05435066
Recruiting
This is a prospective, multi-center, observational study with a collection of biospecimens and clinical data from approximately 10,000 participants from up to 125 clinical network sites and locations in the United States. The objective of this study is to collect blood samples, tissue samples, and associated clinical data from participants with a variety of solid tumor and hematologic cancers and non-cancer participants for testing and the development of a screening test for early cancer detecti... Read More
Gender:
All
Ages:
Between 20 years and 79 years
Trial Updated:
06/04/2024
Locations: Hope Cancer Care of Nevada, Las Vegas, Nevada
Conditions: Cancer
Register for Updates
A Study Evaluating Efruxifermin in Subjects With Non-invasively Diagnosed Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Nonalcoholic Fatty Liver Disease (NAFLD)/Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
NCT06161571
Recruiting
The aim of this study is to assess the safety and tolerability of EFX compared to placebo in subjects with non-invasively diagnosed NASH/MASH and NAFLD/MASLD.
Gender:
All
Ages:
Between 18 years and 80 years
Trial Updated:
06/04/2024
Locations: Akero Clinical Study Site, Las Vegas, Nevada +1 locations
Conditions: NASH/MASH, NAFLD/MASLD
Register for Updates
Selinexor in Maintenance Therapy After Systemic Therapy for Participants With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma
NCT05611931
Recruiting
The purpose of this study is to evaluate the efficacy and safety of selinexor as a maintenance treatment in patients with p53 wt endometrial carcinoma (EC), who have achieved a partial response (PR) or complete response (CR) (per Response Evaluation Criteria in Solid Tumors version 1.1 [RECIST v 1.1]) after completing at least 12 weeks of platinum-based therapy. A total of 220 participants will be enrolled in the study and randomized in a 1:1 ratio to maintenance therapy with either selinexor or... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
06/04/2024
Locations: Women's Cancer Center of Nevada, Las Vegas, Nevada
Conditions: Endometrial Cancer
Register for Updates
A Study to Investigate the Efficacy and Safety of Verekitug (UPB-101) in Adult Participants With Severe Asthma (VALIANT)
NCT06196879
Recruiting
The purpose of this study is to evaluate the efficacy and safety of verekitug (UPB-101) in participants with severe asthma. The study will evaluate the incidence of asthma exacerbations, other pharmacodynamic (PD) parameters such as lung function and asthma control, and the safety and tolerability of verekitug (UPB-101) compared to placebo.
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
06/04/2024
Locations: M3 Wake Research, Las Vegas, Nevada
Conditions: Severe Asthma
Register for Updates